公开(公告)号：US20220267346A1

公开(公告)日：2022-08-25

申请号：US17624572

申请日：2019-07-02

Applicant: SUNSHINE LAKE PHARMA CO., LTD.

Inventor： Zheng GU ,  Wanjun TANG ,  Xinye YANG ,  Xuli WANG ,  Weihui YUAN ,  Yunzeng CUI ,  Wen YANG ,  Jianyu LIU ,  Yingjun ZHANG

IPC: C07D495/04

Abstract: Thienopyrimidine derivative having stereo configurations and use thereof in medicine. Also included are pharmaceutical compositions of the compounds. The compounds or pharmaceutical compositions may be used to inhibit acetyl-CoA carboxylase (ACC). A method for preparing the compounds and the pharmaceutical compositions, and use thereof in treatment or prevention of diseases associated with ACC regulation of mammals, in particular, humans.

公开(公告)号：US20180230102A1

公开(公告)日：2018-08-16

申请号：US15750205

申请日：2016-08-31

Applicant: SUNSHINE LAKE PHARMA CO., LTD.

Inventor： Xinye YANG ,  Changwei HUANG ,  Facheng MA ,  Ji ZHANG ,  Xiaojun WANG ,  Yingjun ZHANG

IPC: C07D215/48 ,  A61K31/47 ,  C07D209/42 ,  A61K31/404 ,  C07D307/85 ,  A61K31/343 ,  C07C255/57 ,  A61K31/277 ,  C07D307/84 ,  C07D261/20 ,  A61K31/423 ,  C07D209/10 ,  C07D277/56 ,  A61K31/426 ,  C07D249/18 ,  A61K31/4192 ,  C07D231/56 ,  A61K31/416 ,  C07D317/68 ,  A61K31/36 ,  C07D307/83 ,  C07D209/08 ,  C07D213/79 ,  A61K31/4418 ,  C07D215/18 ,  C07D215/16 ,  C07D215/06 ,  C07D333/62 ,  A61K31/381 ,  C07D333/70 ,  C07D471/04 ,  A61K31/437 ,  C07D235/06 ,  A61K31/4184 ,  C07D263/56 ,  C07D277/64 ,  A61K31/428 ,  C07D487/04 ,  A61K31/519 ,  C07D405/04 ,  A61K31/443 ,  C07D237/30 ,  A61K31/502 ,  A61K45/06 ,  A61P13/02

CPC classification number: C07D215/48 ,  A61K31/277 ,  A61K31/33 ,  A61K31/343 ,  A61K31/36 ,  A61K31/381 ,  A61K31/404 ,  A61K31/416 ,  A61K31/4184 ,  A61K31/4192 ,  A61K31/42 ,  A61K31/423 ,  A61K31/426 ,  A61K31/428 ,  A61K31/437 ,  A61K31/44 ,  A61K31/4418 ,  A61K31/443 ,  A61K31/47 ,  A61K31/502 ,  A61K31/517 ,  A61K31/519 ,  A61K45/06 ,  A61P13/02 ,  C07C255/57 ,  C07C2602/06 ,  C07C2602/08 ,  C07D209/04 ,  C07D209/08 ,  C07D209/10 ,  C07D209/30 ,  C07D209/42 ,  C07D213/79 ,  C07D215/02 ,  C07D215/06 ,  C07D215/16 ,  C07D215/18 ,  C07D231/56 ,  C07D235/06 ,  C07D235/08 ,  C07D237/28 ,  C07D237/30 ,  C07D249/18 ,  C07D261/20 ,  C07D263/54 ,  C07D263/56 ,  C07D277/56 ,  C07D277/64 ,  C07D291/08 ,  C07D307/79 ,  C07D307/82 ,  C07D307/83 ,  C07D307/84 ,  C07D307/85 ,  C07D317/64 ,  C07D317/68 ,  C07D333/54 ,  C07D333/62 ,  C07D333/70 ,  C07D405/04 ,  C07D471/04 ,  C07D487/04

Abstract: Carboxy-substituted (hetero)aryl derivatives, pharmaceutical compositions comprising these compounds, and methods of preparing such compounds and compositions are provided. The compounds or compositions are useful in inhibiting xanthine oxidase and urate anion transporter 1, and also can be used in the treatment or prevention of diseases associated with high blood uric acid level in mammals, especially humans.

公开(公告)号：US20220389024A1

公开(公告)日：2022-12-08

申请号：US17779452

申请日：2020-11-27

Applicant: SUNSHINE LAKE PHARMA CO., LTD.

Inventor： Yuefeng SHAN ,  Liang CHEN ,  Xinye YANG ,  Xiaojun WANG

IPC: C07D491/044

Abstract: A crystalline form A of a nitrogen-containing tricyclic compound shown in formula (I), a pharmaceutical composition containing the crystalline form A, and the use of the crystalline form A or the pharmaceutical composition in the preparation of a medication for preventing, treating or relieving an FXR-mediated disease of a patient.

公开(公告)号：US20190352311A1

公开(公告)日：2019-11-21

申请号：US16476290

申请日：2018-01-22

Applicant: SUNSHINE LAKE PHARMA CO., LTD. ,  NORTH & SOUTH BROTHER PHARMACY INVESTMENT COMPANY LIMITED

Inventor： Wanjun TANG ,  Xinye YANG ,  Zheng GU ,  Chenlu LI ,  Zongyuan ZHANG ,  Zhifu WAN ,  Xiaojun WANG ,  Yingjun ZHANG

IPC: C07D495/04 ,  C07D519/00

Abstract: The present invention relates to a thienopyrimidine derivative and use thereof in medicine, and also to a pharmaceutical composition containing the compound. The compound or pharmaceutical composition is used for inhibiting acetyl-CoA carboxylase (ACC). The present invention also relates to a method of preparing such compound and pharmaceutical composition, as well as their use in the treatment or prevention of diseases regulated by acetyl-CoA carboxylase in mammals, especially in humans.

公开(公告)号：US20190169203A1

公开(公告)日：2019-06-06

申请号：US16322945

申请日：2017-08-02

Applicant: SUNSHINE LAKE PHARMA CO., LTD.

Inventor： Xiaojun WANG ,  Xinye YANG ,  Junwen WU ,  Shaohui XIONG ,  Shengqiang PAN ,  Shengtian CAO ,  Yingjun ZHANG

IPC: C07D491/044 ,  C07D491/056 ,  C07D491/107

Abstract: A nitrogen-containing tricyclic compound which acts as modulator of FXR, or a stereoisomer, a geometric isomer, a tautomer, an N-oxide, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, and the use of the compound for the treatment of disease and/or condition mediated by FXR are described. And a pharmaceutical composition containing the compound disclosed herein and a method of treatment of disease and/or condition mediated by FXR comprising administering the compound or the pharmaceutical composition thereof are also described.

公开(公告)号：US20240409549A1

公开(公告)日：2024-12-12

申请号：US18700870

申请日：2022-10-14

Applicant: SUNSHINE LAKE PHARMA CO., LTD.

Inventor： Xinye YANG ,  Yuefeng SHAN ,  Liang CHEN ,  Xiaojun WANG

IPC: C07D491/107 ,  A61K31/4353

Abstract: A new crystal form and use of a nitrogenous tricyclic compound in the field of drugs. Specifically, a new crystal form of 2-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)-10H-spiro[benzo[6,7]oxepino[3,2-b]pyridine-11,1′-cyclopropane]-7-carboxylic acid, and the new crystal form is a crystal form I. A pharmaceutical composition including the crystal form I, and the use of the crystal form I or the pharmaceutical composition in preparation of a drug for preventing, treating, or relieving an FXR-mediated disease of a patient.

公开(公告)号：US20230002400A1

公开(公告)日：2023-01-05

申请号：US17779197

申请日：2020-11-27

Applicant: SUNSHINE LAKE PHARMA CO., LTD.

Inventor： Xinye YANG ,  Liang CHEN ,  Yuefeng SHAN ,  Xiaojun WANG

IPC: C07D491/044

Abstract: An amorphous form of a nitrogen-containing tricyclic compound and a use thereof, a pharmaceutical composition containing the compound in the amorphous form, and the use of the compound in the amorphous form or the pharmaceutical composition in the preparation of a drug for preventing, treating or alleviating FXR-mediated diseases in a patient.

公开(公告)号：US20180030003A1

公开(公告)日：2018-02-01

申请号：US15541018

申请日：2016-02-05

Applicant: Sunshine Lake Pharma Co., Ltd.

Inventor： Xiaojun WANG ,  Xinye YANG ,  Shengqiang PAN ,  Rui GUO ,  Junwen WU ,  Yingjun ZHANG ,  Changchung CHENG

IPC: C07D261/08 ,  C07D491/147 ,  C07D491/052 ,  C07D249/06 ,  C07D413/12 ,  C07D491/044

CPC classification number: C07D261/08 ,  A61K31/42 ,  A61K31/4353 ,  A61K31/4985 ,  A61K31/519 ,  C07D249/06 ,  C07D411/12 ,  C07D413/12 ,  C07D471/04 ,  C07D491/044 ,  C07D491/052 ,  C07D491/147 ,  C07D497/04 ,  C07D498/04 ,  C07D498/14

Abstract: The present invention relates to novel tricyclic compounds which can bind to FXR and act as modulators of the FXR, or a stereoisomer, a geometric isomer, a tautomer, an N-oxide, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, and the uses of the compounds for the treatment of diseases and/or conditions mediated by FXR. The invention further provides a pharmaceutical composition containing the compound disclosed herein and a method of treatment of diseases and/or conditions mediated by FXR comprising administering the compound or the pharmaceutical composition.